# A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

> **NCT05643742** · PHASE1,PHASE2 · RECRUITING · sponsor: **CRISPR Therapeutics AG** · enrollment: 120 (estimated)

## Conditions studied

- B-cell Lymphoma
- Non-Hodgkin Lymphoma
- B-cell Malignancy
- Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CTX112

## Key facts

- **NCT ID:** NCT05643742
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-10
- **Primary completion:** 2030-01
- **Final completion:** 2030-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643742, "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05643742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*